Table 1 Baseline characteristic of four eligible studies not include Muren et al. and Kumar et al. in the meta-analysis
Studies | Year | Study design | Country | No. of patients | Mean age | Female patients | Interventon | Follow up | |
|---|---|---|---|---|---|---|---|---|---|
(E/P) | (E/P) | (E/P) | Experimental | Placebo | |||||
Kinov | 2005 | RCT | Bulgaria | 12/12 | 58.3/56 | 8/7 | 35 mg risedronate | Placebo | 6 months |
Yamasaki | 2006 | RCT | Japan | 19/21 | 66.8/66.7 | 17/19 | 2.5 mg/d risedronate | Placebo | 6 months |
Skoldenberg | 2011 | RCT | Sweden | 36/37 | 61.2/60.3 | 22/21 | 35 mg risedronate | Placebo | 1 year |
Yin | 2013 | RCT | China | 13/13 | 61.5/63.7 | 5/6 | 5 mg/d risedronate | Placebo | 6 months |